Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
Alberto Esteban-FernándezCarolina Ortiz CortésSilvia López-FernándezAlejandro Recio MayoralFrancisco Javier Camacho JuradoInés Gómez OteroMaría MolinaLuis Almenar BonetRaquel López-VilellaPublished in: ESC heart failure (2022)
In a real-life cohort of patients with HF, patiromer reduced and maintained K levels during 3 months of follow-up. The most common adverse events were hypomagnesaemia and gastrointestinal disturbances. Patiromer helps optimize medical treatment, increasing the percentage of patients treated with RAASi and MRA at target doses. At the end of follow-up, natriuretic peptides values and hospital visits were reduced, suggesting the benefit of optimizing HF medical treatment.